Israel News Beep
  • News Beep
  • Israel
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
Israel News Beep
Israel News Beep
  • News Beep
  • Israel
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology

Browsing Tag

Reimagine Medicine

12 posts
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

  • March 21, 2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

  • February 27, 2026
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

  • February 27, 2026
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

  • February 25, 2026
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

  • February 23, 2026
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
MMedication
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

  • February 21, 2026
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

  • February 6, 2026
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

  • January 16, 2026
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…
HHealthcare
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis and US government reach agreement on lowering drug prices in the US

  • December 19, 2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

  • October 25, 2025
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

  • October 22, 2025
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in…
BBusiness
Diseases of Aging and Regenerative medicine (DARe) research at Novartis
Read More

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

  • September 26, 2025
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety…
Israel News Beep
www.newsbeep.com